Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Clinical trial NCT05407636 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05407636
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

AMD nAMD Wet Age-related Macular Degeneration wAMD WetAMD CNV

Start date: 2022-01-13
Primary completion: 2026-10-01
Enrollment: 735

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.